ElectroCore, which is engaged in developing non-invasive Vagal Nerve Stimulation, or nVNS, therapies for neurological conditions and bronchoconstriction, has announced that Eric Liebler, co-founder and former president of Nautilus Neurosciences, Inc., has joined ElectroCore as vice president, or VP, of scientific, medical and governmental affairs.
Mr Liebler brings more than 20 years of neurological industry and association experience to ElectroCore. In 2009, he co-founded Nautilus Neurosciences, a neurology-focused specialty pharmaceutical company focused on identifying and developing drugs benefitting those affected by neurological disorders, to market Cambia for the treatment of acute migraine. At Nautilus, Mr Liebler was involved in all facets of the company's organization.
"Eric's deep expertise across many facets of neurology will be a valuable asset to ElectroCore as we continue to grow in the field of non-invasive vagal stimulation," said JP Errico, CEO of ElectroCore. "His industry experience and ability to thrive in an entrepreneurial setting will benefit ElectroCore as we explore nVNS across several serious neurological conditions."
Mr Liebler has held leadership positions at Elan, Amarin, Enzon Pharmaceuticals, Questcor Pharmaceuticals, and Pharmacopeia. He founded Nisola LLC, an advocacy and business strategy-consulting firm focused on serving clients in the field of neurology, and sat on the Board of Trustees of the American Academy of Neurology Foundation (now the American Brain Foundation) for more than a decade. Mr Liebler began his career at Athena Neurosciences.
"ElectroCore's nVNS devices have the potential to be game-changers in a broad range of serious conditions," said Liebler. "I'm thrilled to join a team that's committed to bringing meaningful treatment advances to patients suffering from migraines, cluster headaches and epilepsy."